Cystic kidney disease is associated with a greatest likelihood of progressing to end-stage renal disease, but the small risk of death.
Alvimopan also was found to shorten hospital length of stay.
Benefits observed for moderate consumption, but risk is increased for heavy consumption.
It is associated with fewer positive surgical margins and reduced need for additional treatment.
Increasing health insurance coverage and access to usual source of care necessary to meet targets.